- Home
- IGD vs ARCT Comparison
IGD vs ARCT Comparison
Compare IGD & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGD
- ARCT
- Stock Information
- Founded
- IGD N/A
- ARCT 2013
- Country
- IGD United States
- ARCT United States
- Employees
- IGD N/A
- ARCT N/A
- Industry
- IGD Trusts Except Educational Religious and Charitable
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- IGD Finance
- ARCT Health Care
- Exchange
- IGD Nasdaq
- ARCT Nasdaq
- Market Cap
- IGD 421.2M
- ARCT 487.0M
- IPO Year
- IGD N/A
- ARCT N/A
- Fundamental
- Price
- IGD $5.34
- ARCT $16.59
- Analyst Decision
- IGD
- ARCT Strong Buy
- Analyst Count
- IGD 0
- ARCT 7
- Target Price
- IGD N/A
- ARCT $65.00
- AVG Volume (30 Days)
- IGD 215.3K
- ARCT 419.2K
- Earning Date
- IGD 01-01-0001
- ARCT 03-06-2025
- Dividend Yield
- IGD 9.15%
- ARCT N/A
- EPS Growth
- IGD N/A
- ARCT N/A
- EPS
- IGD N/A
- ARCT N/A
- Revenue
- IGD N/A
- ARCT $160,399,000.00
- Revenue This Year
- IGD N/A
- ARCT $7.33
- Revenue Next Year
- IGD N/A
- ARCT $4.71
- P/E Ratio
- IGD N/A
- ARCT N/A
- Revenue Growth
- IGD N/A
- ARCT N/A
- 52 Week Low
- IGD $4.60
- ARCT $14.30
- 52 Week High
- IGD $5.26
- ARCT $45.00
- Technical
- Relative Strength Index (RSI)
- IGD 41.61
- ARCT 44.94
- Support Level
- IGD $5.25
- ARCT $16.01
- Resistance Level
- IGD $5.48
- ARCT $21.26
- Average True Range (ATR)
- IGD 0.06
- ARCT 1.39
- MACD
- IGD -0.01
- ARCT 0.08
- Stochastic Oscillator
- IGD 30.36
- ARCT 23.82
About IGD Voya Global Equity Dividend and Premium Opportunity Fund
Voya Global Equity Dividend and Premium Opportunity Fund are a United States-based diversified, closed-end Fund. The primary objective of the Fund is to seek to provide investors with a high level of income from a portfolio of common stocks with historically attractive dividend yields and premiums from call option writing. The secondary investment objective of the company is capital appreciation. Under normal market conditions, the Fund will invest at least 80% of its managed assets in a portfolio of common stocks of dividend-paying companies located throughout the world.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.